Marker Therapeutics Inc

+0.03 (+1.78%)
Earnings Announcements

Marker Therapeutics Reports Qtrly Loss Per Share $0.16

Published: 11/09/2020 22:04 GMT
Marker Therapeutics Inc (MRKR) - Marker Therapeutics Reports Third Quarter 2020 Operating and Financial Results.
Marker Therapeutics - Received Alternate Reagent, Expect to Submit Required Data for Removal of Partial Clinical Hold for Ind for Mt-401 by Q1 2021.
Marker Therapeutics Inc - at September 30, 2020, Marker Had Cash and Cash Equivalents of $27.0 Million.
Marker Therapeutics Inc - Qtrly Loss per Share $0.16.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.16

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.17

More details on our Analysts Page.